Opinion|Videos|September 10, 2024
Closing
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do minimally invasive surgical therapies (MIST) options fit into the evolving landscape of treatments for benign prostate dysplasia; why should urologists consider MIST options for their patients?
- What unmet needs remain in the treatment of BPH, and are there any current trials/investigations in these topics?
Advertisement
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5